Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN ...
Discover how Apellis Pharmaceuticals, Inc. surpasses Q4 expectations with impressive revenue growth and cost reductions.
In February, Bavarian Nordic received marketing authorization in Europe for VIMKUNYA ® for persons 12 years of age and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback